JZJiayi Zhao

Jiayi Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiayi Zhao has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Transcriptome to Therapy: The ncRNA Revolution in Neurodevelopmental Disorders

    by Jiayi Zhao, Shanshan Li, Xin Jin

    Neurodevelopmental disorders (NDDs) such as autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and intellectual disability (ID) arise from disruptions of molecular programmes that coordinate neurogenesis, synaptogenesis, and circuit maturation. While genomic studies have identified numerous susceptibility loci, genetic variation alone accounts for only part of disease heritability, underscoring the importance of post-transcriptional and epigenetic regulation. Among these regulatory layers, non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), PIWI-interacting RNAs (piRNAs), and transfer RNA-derived small RNAs (tsRNAs), have emerged as central modulators of neural differentiation, synaptic plasticity, and intercellular signalling. Recent multi-omics and single-cell studies reveal that ncRNAs fine-tune chromatin accessibility, transcriptional output, and translation through tightly integrated regulatory networks. miRNAs shape neurogenic transitions and circuit refinement; lncRNAs and circRNAs couple chromatin architecture to activity-dependent transcription; and tsRNAs and piRNAs extend this regulation by linking translational control to epigenetic memory and environmental responsiveness. Spatial transcriptomics further maps ncRNA expression to vulnerable neuronal and glial subtypes across cortical and subcortical regions. Clinically, circulating ncRNAs, especially those packaged in extracellular vesicles, exhibit stable, disease-associated signatures, supporting their potential as minimally invasive biomarkers for early diagnosis and patient stratification. Parallel advances in RNA interference, antisense oligonucleotides, CRISPR-based editing, and vesicle-mediated delivery highlight emerging therapeutic opportunities. These developments position ncRNAs as both mechanistic determinants and translational targets in NDDs, offering a unifying framework that links genome regulation, environmental cues, and neural plasticity, and paving the way for next-generation RNA-guided diagnostics and therapeutics.


  • Open Access

    From Transcriptome to Therapy: The ncRNA Revolution in Neurodevelopmental Disorders

    by Jiayi Zhao, Shanshan Li, Xin Jin

    Neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD) and intellectual disability (ID), arise from disruptions of tightly orchestrated molecular programmes that govern neurogenesis, synaptogenesis and circuit maturation. Although large-scale genomic analyses have identified numerous susceptibility loci, DNA variation alone explains only a fraction of disease heritability, highlighting the pivotal contribution of post-transcriptional and epigenetic regulation. Among these regulatory layers, non-coding RNAs (ncRNAs)—encompassing microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), PIWI-interacting RNAs (piRNAs) and transfer-RNA-derived small RNAs (tsRNAs)—have emerged as key modulators of neural differentiation, synaptic plasticity and intercellular communication. Multi-omics studies reveal that ncRNAs fine-tune chromatin accessibility, transcriptional output and translation through complex competing-endogenous-RNA (ceRNA) and ribonucleoprotein networks. While miRNAs sculpt neurogenesis and circuit remodelling, lncRNAs and circRNAs integrate chromatin and transcriptional control with exquisite spatial and temporal precision. Newly characterized small RNAs such as tsRNAs and piRNAs extend this regulatory repertoire by linking translational reprogramming, epigenetic memory and even intergenerational inheritance. Advances in single-cell and spatial transcriptomics have further mapped ncRNA expression to discrete neuronal and glial populations, revealing cell-type-specific vulnerability signatures across cortical and subcortical regions. Clinically, circulating ncRNAs—particularly those encapsulated within plasma or extracellular vesicles—exhibit robust and disease-specific expression patterns, supporting their promise as non-invasive biomarkers for early diagnosis and patient stratification. In parallel, innovations in RNA interference, antisense oligonucleotides, CRISPR-based editing and exosome-mediated delivery are transforming ncRNAs from molecular indicators into therapeutic instruments capable of restoring transcriptional and epigenetic equilibrium. Together, these converging insights position ncRNAs as both mechanistic determinants and translational targets in neurodevelopmental pathology. The emerging ncRNA landscape redefines the molecular architecture of brain development, offering a unifying framework that links genome regulation, environmental responsiveness and neural plasticity. Decoding this multilayered RNA circuitry will be pivotal for the development of next-generation diagnostics and RNA-guided therapies for neurodevelopmental disorders.